GSK Management

Management criteria checks 3/4

GSK's CEO is Emma Walmsley, appointed in Apr 2017, has a tenure of 5.25 years. total yearly compensation is £8.20M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth CHF24.97M. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.

Key information

Emma Walmsley

Chief executive officer

UK£8.2m

Total compensation

CEO salary percentage	14.9%
CEO tenure	5.3yrs
CEO ownership	0.03%
Management average tenure	4.3yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Emma Walmsley's remuneration changed compared to GSK's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	UK£5b
Dec 31 2021	UK£8m	UK£1m	UK£4b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£6b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Compensation vs Market: Emma's total compensation ($USD9.86M) is above average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Emma's compensation has been consistent with company performance over the past year.

CEO

Emma Walmsley (52 yo)

5.3yrs

Tenure

UK£8,203,000

Compensation

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Emma Walmsley	CEO & Director	5.3yrs	UK£8.20m	0.031% £ 25.0m
Iain Mackay	CFO & Executive Director	3.3yrs	UK£5.29m	0.0055% £ 4.5m
Hal Barron	Chief Scientific Officer	4.3yrs	UK£9.26m	0.023% £ 18.5m
Shobie Ramakrishnan	Chief Digital & Technology Officer	1.5yrs	no data	no data
Sarah Elton-Farr	Head of Investor Relations	no data	no data	no data
James Ford	Senior VP & Group General Counsel of Legal & Compliance	3.9yrs	no data	no data
Sally Jackson	Senior Vice President of Global Communications & CEO Office	3.3yrs	no data	no data
Diana Conrad	Chief People Officer	3.3yrs	no data	no data
David Redfern	Chief Strategy Officer	14.2yrs	no data	no data
Philip Thomson	President of Global Affairs	5.3yrs	no data	0.0030% £ 2.4m
Roger Connor	President of Vaccines & Global Health	9.5yrs	no data	no data
Brian McNamara	Chief Executive Officer of GSK Consumer Healthcare	5.8yrs	no data	no data

4.3yrs

Average Tenure

56yo

Average Age

Experienced Management: 001102657's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Emma Walmsley	CEO & Director	5.5yrs	UK£8.20m	0.031% £ 25.0m
Iain Mackay	CFO & Executive Director	3.5yrs	UK£5.29m	0.0055% £ 4.5m
Hal Barron	Chief Scientific Officer	4.5yrs	UK£9.26m	0.023% £ 18.5m
Jonathan Symonds	Non-Executive Chairman	2.8yrs	UK£703.00k	0.0014% £ 1.1m
Laurie Glimcher	Independent Non-Executive Director	4.8yrs	UK£131.46k	0.0010% £ 824.1k
Urs Rohner	Independent Non-Executive Director	7.5yrs	UK£146.00k	0.00036% £ 293.7k
Dame Cox	Independent Non-Executive Director & Workforce Engagement Director	6yrs	UK£136.00k	0.00024% £ 195.8k
Manvinder Banga	Senior Independent Non-Executive Director	6.8yrs	UK£146.00k	0.0021% £ 1.7m
Lynn Elsenhans	Independent Non-Executive Director	10yrs	UK£135.89k	0.0019% £ 1.5m
Anne Beal	Independent Non-Executive Director	1.2yrs	UK£61.30k	0.000040% £ 32.6k
Charles Bancroft	Independent Non-Executive Director	2.2yrs	UK£158.78k	0.00041% £ 334.5k
Jesse Goodman	Independent Non-Executive Director	6.5yrs	UK£178.72k	0.00045% £ 367.2k

5.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 001102657's board of directors are considered experienced (5.2 years average tenure).

GSK Management

Management criteria checks 3/4

Key information

Recent management updates

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Board Changes

Recent updates

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Gsk plc Revises Earnings Guidance for the Full Year 2023

Gsk plc Announces Positive Headline Results from Planned Analysis of Part 1 of the Ruby/Engot-En6/Gog3031/Nsgo Phase Iii Trial

GSK plc Announces Positive Preliminary Results from its Phase III Trial Evaluating the Immune Response and Safety of Arexvy

GSK plc Receives Positive CHMP Opinion Recommending Approval of Jemperli (Dostarlimab) Plus Chemotherapy as A New Frontline Treatment for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Update on Zantac (Ranitidine) Litigation

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc to Report Q3, 2023 Results on Nov 01, 2023

GSK plc Announces Board Changes

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Approves Arexvy for the Prevention of RSV

US Food and Drug Administration Approves GSK Plc's Ojjaara (Momelotinib) for the Treatment of Intermediate or High-Risk Myelofibrosis, Including Primary Myelofibrosis or Secondary Myelofibrosis

GSK Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese Regulator

Gsk plc Announces Nucala Crswnp Submission Accepted in Japan

GSK plc Announces Positive Results from the First-Ever Efficacy Trial of Shingrix in China

GSK plc Announces AREXVY, Respiratory Syncytial Virus Vaccine, Available At All Major US Retail Pharmacies

GSK plc Announced That the US Food and Drug Administration Approved Jemperli (Dostarlimab) in Combination with Carboplatin and Paclitaxe

GSK plc Announces Dividend for Second Quarter of 2023, Payable on 12 October 2023

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age